This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation.
For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences.
Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately.
This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.
European urology. 2024 Aug 17 [Epub ahead of print]
Paolo Gontero, Alison Birtle, Otakar Capoun, Eva Compérat, José L Dominguez-Escrig, Fredrik Liedberg, Paramananthan Mariappan, Alexandra Masson-Lecomte, Hugh A Mostafid, Benjamin Pradere, Bhavan P Rai, Bas W G van Rhijn, Thomas Seisen, Shahrokh F Shariat, Francesco Soria, Viktor Soukup, Robert Wood, Evanguelos N Xylinas
Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy. Electronic address: ., Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK., Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic., Department of Pathology, Medical University of Vienna, Vienna, Austria., Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Institute of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden., Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, The University of Edinburgh, Edinburgh, UK., Department of Urology, APHP, Saint Louis Hospital, Université de Paris, Paris, France., Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK., Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France., Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France., Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University Vienna, Vienna, Austria., Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy., EAU Guidelines Office, Arnhem, The Netherlands., Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, France.